°Ô³ð ¾Ï °Ë»ç ½ÃÀå : °Ë»ç À¯Çüº°, ¾Ï À¯Çüº°, ±â¼úº°, ÃÖÁ¾»ç¿ëÀÚº°, ¹ÙÀÌ¿À¸¶Ä¿ À¯Çüº°, ¼­ºñ½º Á¦°ø¾÷üº°, Áö¿ªº°
Genomic Cancer Testing Market, By Test Type, By Cancer Type, By Technology, By End-User, By Biomarker Type, By Service Provider, By Application, By Testing Setting, By Geography
»óǰÄÚµå : 1402600
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2023³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è °Ô³ð ¾Ï °Ë»ç ½ÃÀå ±Ô¸ð´Â 2023³â 161¾ï 5,000¸¸ ´Þ·¯¿¡¼­ 2030³â 476¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 16.7%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í ´ë»ó ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2022³â 2023³â ½ÃÀå ±Ô¸ð 161¾ï 5,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030³â
¿¹Ãø ±â°£ÀÇ CAGR 16.70% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 476¾ï 2,000¸¸ ´Þ·¯
±×¸² 1. °Ô³ð ¾Ï °Ë»ç ¼¼°è ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2023³â
Genomic Cancer Testing Market-IMG1

°Ô³ð ¾Ï °Ë»ç´Â Á¾¾çÇÐ ºÐ¾ß¸¦ ºü¸£°Ô º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ °Ë»ç´Â ¾Ï¼¼Æ÷ÀÇ À¯ÀüÀÚ ±¸¼ºÀ» ºÐ¼®ÇÏ¿© ȯÀÚÀÇ Áúº´À» À¯¹ßÇÏ´Â µ¹¿¬º¯ÀÌ¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ ¾ò½À´Ï´Ù. ÀÌ °³º°È­ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ ÀÓ»óÀÇ´Â °³ÀÎÀÇ À¯ÀüÀÚ ÇÁ·ÎÇÊÀ» ±â¹ÝÀ¸·Î Ä¡·á¸¦ Á¶Á¤Çϰí Á¸ÀçÇÏ´Â ÀÌ»óÀ» Á÷Á¢ Ç¥ÀûÀ¸·Î »ï´Â Ä¡·áÁ¦¸¦ ¼±ÅÃÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¾¾ç À¯Àüü ºÐ¼®Àº ƯÁ¤ ¾à¹°¿¡ ´ëÇÑ ¹ÝÀÀÀ» ¿¹ÃøÇϰí, Àç¹ß À§ÇèÀÌ ³ôÀº À¯ÀüÀÚ ¸¶Ä¿¸¦ È®ÀÎÇϰí, ¾Ï ¼ºÀåÀ» ¸·±â À§ÇØ Â÷´ÜÇÒ ¼ö ÀÖ´Â »ý¹°ÇÐÀû °æ·Î¸¦ ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. °Ô³ð ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î ¾Ï °Ë»ç´Â ´õ¿í Æ÷°ýÀûÀ̰í Àú·ÅÇØÁö°í ÀÖ½À´Ï´Ù. ÀÌ´Â ÇâÈÄ ¸î ³â ¾È¿¡ ¸¹Àº ¾Ï ȯÀÚÀÇ °á°ú¸¦ Å©°Ô °³¼±ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è °Ô³ð ¾Ï °Ë»ç ½ÃÀåÀº ÁÖ·Î Àü ¼¼°è ¾Ï ¹ßº´·ü Áõ°¡¿Í ÀÌ¿¡ µû¸¥ Á¤¹ÐÀÇ·á Á¢±Ù¹ý¿¡ ´ëÇÑ ¼ö¿ä¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°À» À§ÇÑ Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS) ±â¼úÀÇ Àû¿ëÀÌ È®´ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÇÏÁö¸¸, ƯÈ÷ °³¹ßµµ»ó±¹¿¡¼­´Â À¯Àüü ºÐ¼®¿¡ ÇÊ¿äÇÑ ÀÎÇÁ¶ó¿Í ¼÷·ÃµÈ Àü¹®°¡°¡ ºÎÁ·ÇÏ´Ù´Â °ÍÀÌ Å« ¹®Á¦Á¡À¸·Î ÁöÀûµÇ°í ÀÖ½À´Ï´Ù. °Ë»ç ÀýÂ÷ÀÇ ³ôÀº ºñ¿ëµµ º¸±ÞÀ» ´õ¿í Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª »õ·Î¿î Áø´Ü µµ±¸¸¦ °³¹ßÇϱâ À§ÇÑ ¹Î°£ ¹× °ø°ø ±â°üÀÇ ÀÚ±Ý Áö¿øÀº À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. Áø´Ü ±â¾÷°ú ¾Ï ¼¾ÅÍÀÇ ÆÄÆ®³Ê½ÊÀº °Ô³ð ÇÁ·ÎÆÄÀϸµ¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ½Ç¿ëÀûÀÎ °Ô³ð º¯È­¸¦ °¨ÁöÇÏ°í µ¿¹Ý Áø´ÜÀ» °ËÁõÇϱâ À§ÇÑ ´Ù¸¥ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê´Â °Ô³ð ¾Ï °Ë»ç ½ÃÀåÀ» ´õ¿í ÀÚ±ØÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ½ÃÀå ÁøÀÔ ±â¾÷ °£ÀÇ Çù·Â °­È­´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 4¿ù ÀΰøÁö´É ¹× Á¤¹ÐÀÇ·á ¼±µµ±â¾÷ÀÎ Tempus´Â ÁøÇ༺ ¶Ç´Â ÀüÀ̼º °©»ó¼± ¼öÁú¾Ï(MTC) ¶Ç´Â ÁøÇ༺ ¶Ç´Â ÀüÀ̼º ºñ°©»ó¼± ¼öÁú¾Ï(ºñ MTC)À» °¡Áø Àû°Ý ȯÀÚ¿¡°Ô À¯Àüü °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇϱâ À§ÇØ °í¾ÈµÈ Eli Lilly and Company°¡ ÈÄ¿øÇÏ´Â »õ·Î¿î ÆÄÆ®³Ê½ÊÀ» ¿À´Ã ¹ßÇ¥Çß½À´Ï´Ù. À̹ø Çù·ÂÀº TempusÀÇ ºÐÀÚ ÇÁ·ÎÆÄÀϸµÀ» ¹«»óÀ¸·Î Á¦°øÇÏ´Â ÇÑÆí, ÀÇ»çµé°ú Çù·ÂÇÏ¿© ±¤¹üÀ§ÇÑ À¯Àüü °Ë»ç¸¦ ÅëÇØ ȯÀڵ鿡°Ô µ¥ÀÌÅÍ¿¡ ±â¹ÝÇÑ Ä¡·á¹ýÀ» Á¦°øÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú °¡Á¤

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ °Ô³ð ¾Ï °Ë»ç ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ °Ô³ð ¾Ï °Ë»ç ½ÃÀå, °Ë»ç À¯Çüº°, 2018-2030³â

Á¦6Àå ¼¼°èÀÇ °Ô³ð ¾Ï °Ë»ç ½ÃÀå, ¾Ï À¯Çüº°, 2018-2030³â

Á¦7Àå ¼¼°èÀÇ °Ô³ð ¾Ï °Ë»ç ½ÃÀå, ±â¼úº°, 2018-2030³â

Á¦8Àå ¼¼°èÀÇ °Ô³ð ¾Ï °Ë»ç ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2018-2030³â

Á¦9Àå ¼¼°èÀÇ °Ô³ð ¾Ï °Ë»ç ½ÃÀå, ¹ÙÀÌ¿À¸¶Ä¿ À¯Çüº°, 2018-2030³â

Á¦10Àå ¼¼°èÀÇ °Ô³ð ¾Ï °Ë»ç ½ÃÀå, ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õº°, 2018-2030³â

Á¦11Àå ¼¼°èÀÇ °Ô³ð ¾Ï °Ë»ç ½ÃÀå, Áö¿ªº°, 2018-2030³â

Á¦12Àå °æÀï »óȲ

Á¦13Àå ¼½¼Ç

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global genomic cancer testing market size is expected to reach US$ 47.62 billion by 2030, from US$ 16.15 billion in 2023, at a CAGR of 16.7% during the forecast period.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 16.15 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 16.70% 2030 Value Projection: US$ 47.62 Bn
Figure 1. Global Genomic Cancer Testing Market Share (%), by Region, 2023
Genomic Cancer Testing Market - IMG1

Genomic cancer testing is rapidly transforming the field of oncology. It involves analyzing the genetic makeup of cancer cells to gain insights into the mutations driving a patient's disease. This personalized approach enables clinicians to tailor treatment based on an individual's genetic profile and select therapeutics that directly target the abnormalities present. The genomic analysis of a tumor helps predict response to certain drugs, checks for genetic markers that may indicate higher risk of recurrence, and pinpoints biological pathways that can be blocked to stop cancer growth. With continued advances in genomic technologies, cancer testing is becoming more comprehensive and affordable. This is expected to significantly improve outcomes for many cancer patients in the coming years.

Market Dynamics:

The global genomic cancer testing market is primarily driven by rising cancer burden worldwide and subsequent demand for precision medicine approaches. Growing application of next-generation sequencing (NGS) technologies for biomarker identification is also fueling market growth. However, lack of infrastructure and skilled professionals required for genomic analysis poses a major challenge, especially in developing nations. High cost of testing procedures further limits widespread adoption. Yet funding from private and public bodies to develop novel diagnostic tools presents lucrative opportunities. Partnerships between diagnostic companies and cancer centers aim to expand access to genomic profiling. Other strategic initiatives to detect actionable genomic alterations and validate companion diagnostics will further stimulate the genomic cancer testing market. MOrevoer, increasing collaboration between market players is expected to drive the market growth over forecast period. For instance, in April 2023, Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration sponsored by Eli Lilly and Company designed to expand access to genomic testing for eligible patients who have advanced or metastatic medullary thyroid cancer (MTC) OR advanced or metastatic non-medullary thyroid cancer (non-MTC). This collaboration offers Tempus' molecular profiling offerings at no cost while simultaneously working with physicians to support them in providing data-driven treatment to their patients with the use of broad-panel genomic testing.

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Genomic Cancer Testing Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Genomic Cancer Testing Market , By Test Type, 2018-2030, (US$ Bn)

6. Global Genomic Cancer Testing Market , By Cancer Type, 2018-2030, (US$ Bn)

7. Global Genomic Cancer Testing Market , By Technology, 2018-2030, (US$ Bn)

8. Global Genomic Cancer Testing Market , By End User, 2018-2030, (US$ Bn)

9. Global Genomic Cancer Testing Market , By Biomarker Type, 2018-2030, (US$ Bn)

10. Global Genomic Cancer Testing Market , By Service Provider, 2018-2030, (US$ Bn)

11. Global Genomic Cancer Testing Market , By Region, 2018-2030, (US$ Bn)

12. Competitive Landscape

13. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â